A Phase I/II Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients with Advanced Cancers
What is the purpose of this trial?
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.
- Isis Pharmaceuticals
- Last Updated:
- Study HIC#: